Cargando…

Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors in Lung Cancer: Will it Outlast the COVID-19 Pandemic?

Patients with lung cancer are particularly vulnerable to complications from coronavirus disease-2019 (COVID-19). Recurrent hospital visits and hospital admission are potential risk factors for acquiring infection with its causative pathogen, severe acute respiratory syndrome coronavirus−2 (SARS-CoV-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sehgal, Kartik, Costa, Daniel B., Rangachari, Deepa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7344199/ https://www.ncbi.nlm.nih.gov/pubmed/32714874 http://dx.doi.org/10.3389/fonc.2020.01193

Ejemplares similares

Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized?
por: Sehgal, Kartik, et al.
Publicado: (2020)

Impact of extended interval dosing of immune checkpoint inhibitors in lung cancer patients during the COVID-19 pandemic
por: Veron, Marie, et al.
Publicado: (2023)

Outlasting a Rare Duodenal Angiosarcoma
por: Kolli, Sindhura, et al.
Publicado: (2019)

COVID-19 in dialysis patients: outlasting and outsmarting a pandemic
por: Hsu, Caroline M., et al.
Publicado: (2020)

Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study
por: Cantini, Luca, et al.
Publicado: (2023)

Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non–small-cell Lung Cancer
por: Sehgal, Kartik, et al.
Publicado: (2021)

Safety and Efficacy of Extended Interval Dosing for Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer During the COVID-19 Pandemic
por: Hijmering-Kappelle, L.B.M., et al.
Publicado: (2022)

Cognitive Impairments Preceding and Outlasting Autoimmune Limbic Encephalitis
por: Gross, Robert, et al.
Publicado: (2016)

Efficacy of Rituximab Outlasts B-Cell Repopulation in Multiple Sclerosis: Time to Rethink Dosing?
por: Claverie, Roxane, et al.
Publicado: (2023)

Dosing Regimens of Immune Checkpoint Inhibitors: Attempts at Lower Dose, Less Frequency, Shorter Course
por: Jiang, Mengjie, et al.
Publicado: (2022)

Advances in immune checkpoint inhibitor combination strategies for microsatellite stable colorectal cancer
por: Ros, Javier, et al.
Publicado: (2023)

179P Efficacy and safety of extended-interval dosing strategy of immune checkpoint inhibitors during the COVID-19 outbreak: Experience from a single center
por: Pierre, C., et al.
Publicado: (2021)

Biomarkers for Immune Checkpoint Inhibitors in Melanoma
por: Kitano, Shigehisa, et al.
Publicado: (2018)

Immune Checkpoint Inhibitors in the Treatment of HCC
por: Donisi, Clelia, et al.
Publicado: (2021)

Strategies for the Construction of Mouse Models With Humanized Immune System and Evaluation of Tumor Immune Checkpoint Inhibitor Therapy
por: Guo, Wenwen, et al.
Publicado: (2021)

Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer
por: Xiong, Wei, et al.
Publicado: (2021)

Multinational Analysis of Estimated Health Care Costs Related to Extended-Interval Fixed Dosing of Checkpoint Inhibitors
por: Goldstein, Daniel A., et al.
Publicado: (2023)

Immune Checkpoint Inhibitor-induced Fanconi Syndrome
por: Farid, Saira, et al.
Publicado: (2020)

Fluoxetine‐induced plasticity in the visual cortex outlasts the duration of the naturally occurring critical period
por: Steinzeig, Anna, et al.
Publicado: (2019)

OUTpatient intravenous LASix Trial in reducing hospitalization for acute decompensated heart failure (OUTLAST)
por: Hamo, Carine E., et al.
Publicado: (2021)

Rethinking the Optimal Duration of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer Throughout the COVID-19 Pandemic
por: Friedlaender, Alex, et al.
Publicado: (2020)

Immune Dysregulation in Cancer Patients Undergoing Immune Checkpoint Inhibitor Treatment and Potential Predictive Strategies for Future Clinical Practice
por: Anderson, Ronald, et al.
Publicado: (2018)

Recent advances in immune checkpoint inhibitors for non-small lung cancer treatment
por: Altaf, Reem, et al.
Publicado: (2022)

Editorial: Immune checkpoint inhibitors in renal cell carcinoma
por: Tykodi, Scott S., et al.
Publicado: (2023)

Radiotherapy plus immune checkpoint inhibitor in prostate cancer
por: Li, Tianjie, et al.
Publicado: (2023)

Immune-checkpoint inhibitors for lung cancer patients amid the COVID-19 pandemic: a case report of severe meningoencephalitis after switching to an extended-interval higher flat-dose nivolumab regimen
por: Pous, Anna, et al.
Publicado: (2021)

Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond?
por: Sehgal, Kartik, et al.
Publicado: (2020)

Severe pulmonary toxicity from immune checkpoint inhibitor treated successfully with intravenous immunoglobulin: Case report and review of the literature
por: Petri, Camille R., et al.
Publicado: (2019)

Hyperprogression After Immune-Checkpoint Inhibitor Treatment: Characteristics and Hypotheses
por: Zang, Hongjing, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges
por: Liu, Hao-Tian, et al.
Publicado: (2021)

Editorial: Biomarkers of Immune-Checkpoint-Inhibitor Immunotherapies in Hepatocellular Carcinomas
por: Guo, Zhanjun, et al.
Publicado: (2022)

Concomitant Medication Effects on Immune Checkpoint Inhibitor Efficacy and Toxicity
por: Sieber, Brendan, et al.
Publicado: (2022)

Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors
por: Irabor, Omoruyi Credit, et al.
Publicado: (2022)

Immune checkpoint inhibitors in advanced and recurrent/metastatic cervical cancer
por: Han, Xiling, et al.
Publicado: (2022)

Immune checkpoint inhibitors for unresectable or metastatic pleomorphic dermal sarcomas
por: Helbig, Doris, et al.
Publicado: (2022)

CDC25C as a Predictive Biomarker for Immune Checkpoint Inhibitors in Patients With Lung Adenocarcinoma
por: Zhang, Wengang, et al.
Publicado: (2022)

Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review
por: Hao, Yuxuan, et al.
Publicado: (2022)

Tumor-Specific Delivery of Immune Checkpoint Inhibitors by Engineered AAV Vectors
por: Reul, Johanna, et al.
Publicado: (2019)

Toxicities of Immune Checkpoint Inhibitors: Itis-Ending Adverse Reactions and More
por: Ellithi, Moataz, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors in Advanced Acral Melanoma: A Systematic Review
por: Zheng, Qingyue, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_eacqe6gtfeh3802n8khuelkrve